Chronic Lymphocytic Leukemia

Javier Pinilla-Ibarz, MD, PhD, associate member, Malignant Hematology and Immunology Program at the H. Lee Moffitt Cancer Center, discusses ongoing research with ibrutinib (Imbruvica) in chronic lymphocytic leukemia. 

Complete marrow clearance of leukemic cells was achieved in 8 of 9 evaluable patients with heavily pretreated or genetically high-risk chronic lymphocytic leukemia who received concurrent treatment with CTL-119 cell therapy and ibrutinib, results of a pilot study showed.

Jan A. Burger, MD, PhD and Javier Pinilla-Ibarz, MD, PhD shed light on the field of CLL and the transformative role of ibrutinib.

An overview of the factors affecting prognosis and treatment in chronic lymphocytic leukemia.

Current treatment strategies for chronic lymphocytic leukemia (CLL).

<p>CLL is a malignancy characterized by the clonal proliferation and accumulation of small, mature-appearing CD5-positive B lymphocytes in the blood, bone marrow, and secondary lymphoid tissues.</p>

Ublituximab (TG-1101) in combination with ibrutinib (Imbruvica) met its primary endpoint of showing an improvement in objective response rate (ORR) compared with ibruitinib monotherapy in patients with previously treated high-risk chronic lymphocytic leukemia (CLL). In a presentation of findings from the phase III GENUINE trial during the 2017 ASCO Annual Meeting, data were reviewed demonstrating that the combination had an ORR of 78% in this patient population.&nbsp;

Lenalidomide consolidation therapy following induction with fludarabine and rituximab (Rituxan) was found to increase long-term survival over survival rates&nbsp;seen with FR or FR plus cyclophosphamide in an overall survival plateau that intrigued researchers when examined in&nbsp;patients with symptomatic, treatment-naive chronic lymphocytic leukemia without an 11q deletion.

Steven Coutre, MD,&nbsp;discusses ongoing efforts to enhance frontline outcomes for patients with CLL.

Patients with chronic lymphocytic leukemia (CLL) who stopped treatment with ibrutinib due to toxicities had longer survival than those who discontinued for other reasons, including progression and Richter transformation, according to the results of a recently published study.

Subcutaneous rituximab has received the FDA&rsquo;s Oncologic Drugs Advisory Committee (ODAC) unanimous (11-0) recommended approval for the treatment of patients with certain blood cancers.

Adding ublituximab to ibrutinib significantly improved objective response rates (ORR) compared with ibrutinib alone for patients with previously treated high-risk chronic lymphocytic leukemia .

Jennifer Brown, MD, PhD, director of the Chronic Lymphocytic Leukemia Center at the Dana-Farber Cancer Institute, associate professor of Medicine at Harvard Medical School, discusses novel agents under investigation for the treatment of chronic&nbsp;lymphocytic leukemia (CLL).

Lead study author Jennifer A. Woyach, MD, discusses a phase II trial of MOR208, which includes cohorts of patients with relapsed/refractory CLL, treatment-na&iuml;ve disease, Richter&rsquo;s transformation, and those with CLL who have been treated with ibrutinib.

Jennifer Woyach, MD, associate professor, Ohio State University, discusses a study combining MOR208 with Lenalidomide for the treatment of chronic lymphocytic leukemia (CLL).&nbsp;

According to recent study findings, the investigational BTK inhibitor acalabrutinib was shown to be well-tolerated and effective in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) who display intolerance to ibrutinib (Imbruvica).

The Society for Immunotherapy of Cancer (SITC) has announced that Paul M. Sondel, MD, PhD, will receive the 2017 Richard V. Smalley, MD Memorial Lectureship Award.

Treatment with the BTK inhibitor BGB-3111 had an objective response rate (ORR) of 96% for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL).

Combining the PI3 kinase inhibitor TGR-1202 and ibrutinib (Imbruvica) for patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) demonstrated a high response rate without dose-limiting toxicities (DLTs).

Two-thirds of patients with chronic lymphocytic leukemia that progressed on B-cell receptor pathway inhibitors had objective responses to treatment with venetoclax (Venclexta), results of a small open-label trial showed.

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses a phase II trial combining nivolumab (Opdivo) with ibrutinib (Imbruvica) for chronic lymphocytic leukemia (CLL) and richter transformation (RT) during the American Society of Hematology (ASH) Annual Meeting.<br /> &nbsp;

Combination induction therapy with ibrutinib (Imbruvica) and obinutuzumab (Gazyva) after bendamustine debulking induced a 100% response rate in patients with chronic lymphocytic leukemia (CLL), according to findings from the phase II CLL2-BIG trial.&nbsp;

Lenalidomide as maintenance following first-line immunochemotherapy substantially improves progression-free survival in the treatment of patients with high-risk chronic lymphocytic leukemia (CLL), according to interim analysis of the phase III CLLM1 study.

Findings from the longest follow-up to date evaluating up to 5 years of ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) show that the agent is safe and effective.

Jeffrey Jones, MD, MPH, associate professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, discusses the benefits of venetoclax in chronic lymphocytic luekemia (CLL).

With treatment for newly diagnosed acute myeloid leukemia remaining essentially unchanged over the last 4 decades, researchers are hopeful that the addition of the investigational agent vadastuximab talirine to standard 7+3 induction therapy may improve survival for these patients.&nbsp;

Treatment with the combination of nivolumab (Opdivo) and ibrutinib (Imbruvica) showed encouraging activity and safety in a small phase II study of patients with chronic lymphocytic leukemia and Richter transformation.

Miguel Perales, MD, deputy chief, Adult Bone Marrow Transplant Service, and director, Adult Bone Marrow Transplantation Fellowship Program, gives an overview of the PROGRESS II trial in&nbsp;acute leukemia and myelodysplastic syndrome during the ASH Annual Meeting.

The FDA has granted a full approval and label update to ponatinib (Iclusig) for patients with chronic phase (CP), accelerated phase, or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

When it comes to adverse events and duration of response, next-generation BTK inhibitors in chronic lymphocytic leukemia compare favorably with ibrutinib.